Antiretroviral drug resistance and routine therapy, Cameroon

Emerging Infectious Diseases

Volumn 12, Issue 6, 2006, Pages 1001-1004

  Laurent, Christian ^a   Kouanfack, Charles ^b   Vergne, Laurence ^a   Tardy, Michèle ^b   Zekeng, Léopold ^c,d   Noumsi, Nathalie ^b   Butel, Christelle ^a   Bourgeois, Anke ^a   Mpoudi Ngolé, Eitel ^e   Koulla Shiro, Sinata ^b   Peeters, Martine ^a   Delaporte, Eric ^a  

^a INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^b YAOUNDÉ CENTRAL HOSPITAL   (Cameroon)

^c Laboratoire d'Hygiène Mobile   (Cameroon)

^d National AIDS Program   (Cameroon)

^e Military Hospital   (Cameroon)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; CAMEROON; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE;

EID: 33744940304     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1206.050860     Document Type: Article

References (12)

1. World Health Organization/United Nations Programme on HIV/AIDS. WHO-UNAIDS report. Treating 3 million by 2005: making it happen. [cited 2005 Jun 16]. Available from http://www.who.int/3by5/publications/documents/en/ 3by5StrategyMakingItHappen.pdf
2. Stevens W, Kaye S, Corrah T. Antiretroviral therapy in Africa. BMJ. 2004;328:280-2.
3. Vergne L, Malonga-Louellet G, Mistoul I, Mavoungou R, Mansaray H, Peeters M, et al. Resistance to antiretroviral treatment in Gabon: need for implementation of guidelines on antiretroviral therapy use and HIV-1 drug resistance monitoring in developing countries. J Acquir Immune Defic Syndr. 2002;29:165-8.
4. Adjé C, Cheingsong R, Roels TH, Maurice C, Djomand G, Verbiest W, et al. High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Côte d'Ivoire. J Acquir Immune Defic Syndr. 2001;26:501-6.
5. Richard N, Juntilla M, Abraha A, Demers K, Paxinos E, Galovich J, et al. High prevalence of antiretroviral resistance in treated Ugandans infected with non-subtype B human immunodeficiency virus type 1. AIDS Res Hum Retroviruses. 2004;20:355-64.
6. Laurent C, Meilo H, Guiard-Schmid JB, Mapoure Y, Noël JM, M'Bangué M, et al. Antiretroviral therapy in public and private routine health care clinics in Cameroon: lessons from the Douala antiretroviral (DARVIR) initiative. Clin Infect Dis. 2005;41:108-11.
7. Vergne L, Bourgeois A, Mpoudi-Ngole E, Mougnutou R, Mbuagbaw J, Liegeois F, et al. Biological and genetic characteristics of HIV infections in Cameroon reveals dual group M and O infections and a correlation between SI-inducing phenotype of the predominant CRF02_AG variant and disease stage. Virology. 2003;310:254-66.
8. Vergne L, Peeters M, Mpoudi-Ngole E, Bourgeois A, Liegeois F, Toure-Kane C, et al. Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients. J Clin Microbiol. 2000;38:3919-25.
9. Bourgeois A, Laurent C, Mougnutou R, Nkoué N, Lactuock B, Ciaffi L, et al. Field assessment of generic antiretroviral drugs: a prospective cohort study in Cameroon. Antivir Ther. 2005;10:335-41.
10. Vergne L, Touré Kane C, Laurent C, Diakhaté N, Ngom Gueye NF, Gueye PM, et al. Low rate of genotypic HIV-1 drug-resistant strains in the Senegalese government initiative of access to antiretroviral therapy. AIDS. 2003;17(Suppl 3):S31-8.
11. Lanièce I, Ciss M, Desclaux A, Diop K, Mbodj F, Ndiaye B, et al. Adherence to HAART and its principal determinants in a cohort of Senegalese adults. AIDS. 2003;17(Suppl 3):S103-8.
12. Laurent C, Kouanfack C, Koulla-Shiro S, Nkoué N, Bourgeois A, Calmy A, et al. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet. 2004;364:29-34.